<SEC-DOCUMENT>0000950170-24-086643.txt : 20240725
<SEC-HEADER>0000950170-24-086643.hdr.sgml : 20240725
<ACCEPTANCE-DATETIME>20240725172811
ACCESSION NUMBER:		0000950170-24-086643
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240725
DATE AS OF CHANGE:		20240725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268603
		FILM NUMBER:		241142996

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>scilex_424b3_7.25.2024_s.htm
<DESCRIPTION>424B3
<TEXT>
<html>
 <head>
  <title>424B3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filed Pursuant to Rule 424(b)(3)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration No. 333-268603</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PROSPECTUS SUPPLEMENT NO. 5</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(to Prospectus dated March 29, 2024)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Scilex Holding Company</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Up to 71,459,469 Shares of Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Up to 5,490,617 Warrants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid #000000;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This prospectus supplement supplements the prospectus dated March 29, 2024 (the &#x201c;Prospectus&#x201d;), which forms a part of our registration statement on Form S-1 (No. 333-268603) for which Post-Effective Amendment No. 2 was filed with the Securities and Exchange Commission on March 27, 2024 and declared effective by the Securities and Exchange Commission on March 29, 2024. This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 25, 2024 (the &#x201c;Current Report&#x201d;). Accordingly, we have attached the Current Report to this prospectus supplement.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Prospectus and this prospectus supplement relate to the issuance by us of up to an aggregate of 11,003,988 shares of our common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;), issuable upon the exercise of (i) 4,104,000 private placement warrants (the &#x201c;Private Warrant Shares&#x201d;) originally sold in a private placement at a price of $0.75 per warrant in connection with the initial public offering of Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;) (and a portion of which were subsequently transferred to Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;) at no cost in connection with the Business Combination (as defined below)) (the &#x201c;Private Warrants&#x201d;) and (ii) 6,899,988 public warrants (the &#x201c;Public Warrant Shares&#x201d;) originally sold to the public investors in connection with the initial public offering of units of Vickers (the &#x201c;Public Warrants&#x201d; and together with the Private Warrants, the &#x201c;Warrants&#x201d;) at a price of $10.00 per unit, with each unit consisting of one ordinary share of Vickers and one-half of one warrant to purchase one ordinary share of Vickers.  As previously disclosed in prospectus supplement no. 16 to the Prospectus, filed with the Securities and Exchange Commission on October 6, 2023, Sorrento subsequently sold (a) 60,068,585 shares of Common Stock; (b) 29,057,097 shares of Series A Preferred Stock; and (c) warrants exercisable for 4,490,617 shares of Common Stock, in each case to us by delivery of such purchased securities to SCLX Stock Acquisition JV LLC, a Texas limited liability company (&#x201c;SCLX JV&#x201d;) and our indirect wholly-owned subsidiary, of which warrants exercisable for 4,000,000 shares of Common Stock were subsequently transferred by SCLX JV to Oramed Pharmaceuticals, Inc., a Delaware corporation (&#x201c;Oramed&#x201d;).</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Warrant entitles the holder thereof to purchase one share of our Common Stock at a price of $11.50 per share. We will not receive the proceeds from the resale of the Private Warrant Shares or the Public Warrant Shares hereunder; however, we will receive the proceeds from any exercise of the Private Warrants and the Public Warrants.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Prospectus and this prospectus supplement also relates to the offer and sale from time to time by:</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) the selling stockholders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest) (collectively, the &#x201c;Selling Stockholders&#x201d;) of up to an aggregate of 71,459,469 shares (the &#x201c;Resale Shares&#x201d;) of our Common Stock, consisting of:</font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(i) up to 3,983,057 shares of Common Stock (the &#x201c;Sponsor Shares&#x201d;) held by Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Pei Wei Woo, Suneel Kaji and Steve Myint (collectively, the &#x201c;Sponsors&#x201d;), comprised of 3,450,000 shares that were issued on November 9, 2022 upon conversion of the same number of our former ordinary shares (initially acquired by the Sponsors prior to the initial public offering of units of Vickers Vantage Corp. I at a purchase price of $0.007 per ordinary share) in connection with the Domestication and the Business Combination (each as defined below) and 533,057 shares that were also issued on November 9, 2022 upon the contribution of certain indebtedness by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd at a contribution value of $10.00 per share, in connection with the Business Combination pursuant to a debt contribution agreement;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ii) up to 61,985,795 shares of Common Stock (the &#x201c;Merger Shares&#x201d;) issued to Sorrento on November 10, 2022 in connection with the Business Combination at an equity consideration value of $10.00 per share, of which 60,068,585 are now held by SCLX JV;</font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(iii) up to 4,104,000 Private Warrant Shares issuable to certain Selling Securityholders upon the exercise of the Private Warrants at an exercise price of $11.50 per share; and</font></p>
  <p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(iv) up to 1,386,617 Public Warrant Shares issuable to certain Selling Securityholders upon the exercise of the Public Warrants at an exercise price of $11.50 per share; and</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) the selling warrantholders named in this prospectus (including their permitted transferees, donees, pledgees and other successors-in-interest) (collectively, the &#x201c;Selling Warrantholders&#x201d; and, together with the Selling Stockholders, the &#x201c;Selling Securityholders&#x201d;) of up to 4,104,000 Private Warrants (which were originally issued at a price of $0.75 per Private Warrant, of which 3,104,000 were transferred from the Sponsors to Sorrento at no cost in connection with the Business Combination), and 1,386,617 Public Warrants (which were acquired by Sorrento in open-market purchases at a weighted average purchase price of $0.3078 per Public Warrant).  Sorrento subsequently transferred 4,490,617 warrants held by it to SCLX JV, of which 4,000,000 warrants were subsequently transferred by SCLX JV to Oramed.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#x201c;SCLX&#x201d;. On July 24, 2024, the last reported sales price per share of our Common Stock was $1.71. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol &#x201c;SCLXW.&#x201d; On July 24, 2024, the closing sale price per warrant of our Public Warrants was $0.35.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See the section entitled &#x201c;Risk Factors&#x201d; beginning on page 14 of the Prospectus as well as risks and uncertainties described under similar headings in any amendments or supplements to the Prospectus to read about factors you should consider before buying our securities.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The date of this prospectus supplement is July 25, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">FORM 8-K<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d)<br>OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): July 21, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">_______________________<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SCILEX HOLDING COMPANY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br>(Exact name of registrant as specified in its charter)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.32%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware<br>(State or other jurisdiction<br>of incorporation)</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39852<br>(Commission<br>File Number)</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92-1062542<br>(IRS Employer<br>Identification No.)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">960 San Antonio Road, Palo Alto, California, 94303<br>(Address of principal executive offices, including zip code)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (650) 516-4310</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N/A<br>(Former name or former address, if changed since last report)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.26%;"></td>
    <td style="width:94.74%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:35.58%;"></td>
    <td style="width:21.16%;"></td>
    <td style="width:43.26%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common stock, par value $0.0001 per share</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SCLX</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SCLXW</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company &#9746;</font></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:1.5pt double;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9746;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.02.	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 21, 2024, Scilex Holding Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) appointed Annu Navani, M.D. as a Class II director of the Company and as a member of the Commercialization and Transaction Committee of the Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Navani, age 54, founded and has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008 as a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. She has also been serving as the Chief Medical Officer at Boomerang Healthcare since May 2022. Over the last decade, she has scaled a solo practice to a large multispecialty group practice with more than twenty service lines that operate via multiple state of the art centers in Northern and Southern California. Since 2003, Dr. Navani has served as a Clinical Professor in the Division of Pain Medicine at Stanford University School of Medicine. She has also served as an Advisor to Le Reve Regenerative Wellness, the center for cutting edge restorative and regenerative solutions for clinical applications and research, since 2013. Dr. Navani completed her Anesthesiology residency at the Medical College of Wisconsin, Milwaukee and Fellowship in Pain Medicine at the University of California, Davis. She is board certified in Anesthesiology and Pain Medicine by American Board of Anesthesiology, in Interventional Pain by American Board of Interventional Pain Physicians and in Regenerative Medicine by American Board of Regenerative Medicine.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with her appointment to the Board, in accordance with the Company&#x2019;s Non-Employee Director Compensation Policy, Dr. Navani will be granted an initial stock option to purchase 250,000 shares of common stock, which will vest monthly over a period of 48 months from the date of grant, subject to her continued service on the Board through each vesting date.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no family relationships between Dr. Navani and any director or executive officer of the Company, and she was not selected by the Board to serve as a director pursuant to any arrangement or understanding with any person.  Dr. Navani has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will also enter into an indemnification agreement with Dr. Navani in the same form as its standard form of indemnity agreement with its other directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01. 	Other Events.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 23, 2024, the Company issued a press release announcing the appointment of Annu Navani, M.D. as a new director of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01.  Financial Statements and Exhibits.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</font></p>
  <p style="text-indent:-6.929%;padding-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99.1	</font><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1820190/000095017024086629/sclx-20240721.htm"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Press Release, dated July 23, 2024.</font><font style="color:#0000ff;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></a><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-6.929%;padding-left:6.48%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46%;"></td>
    <td style="width:6%;"></td>
    <td style="width:48%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SCILEX HOLDING COMPANY</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jaisim Shah</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jaisim Shah</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: July 25, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and President</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	                             FOR IMMEDIATE RELEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">											     July 23, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><img src="img173561143_0.jpg" alt="img173561143_0.jpg" style="width:282px;height:69px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">PALO ALTO, CALIFORNIA &#x2013; July 23, 2024 (GLOBE NEWSWIRE) - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Scilex Holding Company (Nasdaq: SCLX, &#x201c;Scilex&#x201d; or the &#x201c;Company&#x201d;), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over the last decade, she has scaled her solo practice into a large multispecialty group with more than twenty service lines operating across multiple state-of-the-art centers in Northern and Southern California. In 2022, Dr. Navani sold the practice to a private equity group and now serves as the Chief Medical Officer of Boomerang Healthcare, which has nearly thirty locations in California. Since 2003, Dr. Navani has also served as an Adjunct Clinical Associate Professor in the Division of Pain at Stanford University School of Medicine. Additionally, she has been the Medical Director at Le Reve Regenerative Wellness, a center for cutting-edge regenerative and wellness solutions, for more than a decade. Dr. Navani completed her Anesthesiology residency at the Medical College of Wisconsin, Milwaukee, and her Fellowship in Pain Medicine at the University of California, Davis. She is board certified in Anesthesiology and Pain Medicine by the American Board of Anesthesiology, Interventional Pain by the American Board of Interventional Pain Physicians, and Regenerative Medicine by the American Board of Regenerative Medicine. Dr. Navani serves on the board of several professional organizations, including the American Society of Interventional Pain Physicians, The Ortho Biologic Institute Networks, and the Latin American Pain Society. She has extensive publications in multidisciplinary pain management and has authored several national guidelines, including those on opioids, interventional spine procedures, and biologics. Dr. Navani is a global authority on healthcare trends, including digital health, technology innovations, and applied biologics.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;I am thrilled to join the Scilex Board of Directors, a company known for its innovative work in non-opioid pain management therapies. I look forward to collaborating with my fellow board members and the talented team at Scilex to further advance the development of transformative pain management treatments that have the potential to change lives,&#x201d; said Annu Navani, M.D.</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Page | </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;It is with great pleasure that we welcome Dr. Annu Navani to the Scilex Board of Directors during this exciting time of growth at the company.  Building on our achievement of multiple transformational milestones, we believe Annu&#x2019;s significant track record in academia and private practice in sports and pain medicine will serve Scilex well as we look to progress our commercial non-opioid and innovative pipeline of investigational products to deliver acute and chronic pain therapies faster and more reliably, and will add additional important Board-level expertise to the guidance and oversight of our pain management therapy programs,&#x201d; said Jaisim Shah, Chief Executive Officer and President of Scilex.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information on Scilex Holding Company, refer to </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.scilexholding.com</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information on ZTlido&#174; including Full Prescribing Information, refer to </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.ztlido.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information on ELYXYB&#174;, including Full Prescribing Information, refer to </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.elyxyb.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information on Gloperba</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, including Full Prescribing Information, refer to </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.gloperba.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><img src="img173561143_1.jpg" alt="img173561143_1.jpg" style="width:30px;height:30px;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">   </font><img src="img173561143_2.jpg" alt="img173561143_2.jpg" style="width:26px;height:26px;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">     </font><img src="img173561143_3.jpg" alt="img173561143_3.jpg" style="width:30px;height:23px;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">      </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Scilex Holding Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes.   Scilex&#x2019;s commercial products include: (i) ZTlido&#174; (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB&#174;, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba&#174;, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (&#x201c;SEMDEXA</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; or &#x201c;SP-102&#x201d;), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (&#x201c;SP-103&#x201d;), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which Scilex has recently completed a Phase 2 trial in low back pain.  SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (&#x201c;SP-104&#x201d;), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022.</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Page | </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Scilex Holding Company is headquartered in Palo Alto, California.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected.  Forward&#x2011;looking statements include statements regarding Scilex&#x2019;s development and commercialization plans.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">    </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Risks and uncertainties that could cause Scilex&#x2019;s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets and whether a market will be established for Scilex&#x2019;s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex&#x2019;s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex&#x2019;s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA&#153;), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex&#x2019;s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file, including the risk factors set forth in those filings.  Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Contacts:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors and Media<br>Scilex Holding Company <br>960 San Antonio Road<br>Palo Alto, CA 94303<br>Office: (650) 516-4310</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Email: investorrelations@scilexholding.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Website: </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.scilexholding.com</font></font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Page | </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"># # #</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SEMDEXA&#153; (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company.  A proprietary name review by the FDA is planned.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ZTlido&#174; is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Gloperba&#174; is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ELYXYB&#174; is a registered trademark owned by Scilex Holding Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">All other trademarks are the property of their respective owners.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#169; 2024 Scilex Holding Company All Rights Reserved.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Page | </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img173561143_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173561143_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "3 E@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN#^('
MC]?#<9T[3BLFJ2+DD\B 'N1W/H/Q/O,YJ"NS6C1G6FH06IT/B#Q9H_AJ'?J-
MT!*PRD"?-(_T']3@5YAK'QDU.X=DTFSAM(^SR_O'_P !^M<IHGA_6O&VKRM$
MS2N6W7%W.Q*KGU/<^@%>LZ/\)_#VGQJ;U9-0G[M(Q5,^R@_S)KEYZM7X=$>J
MZ.$PFE7WI?U_6IY5-\0/%<[%FUJX7V0*@_04L'Q!\5V[!EUJ=L=I%5Q^HKV]
M_ OA=TV'1+3'LF#^8YKFM:^#^CW:,^E32V,W9&)DC/Y\C\_PJ70K+5,TACL'
M+W90M\D<YI'QDU*!E35K*&ZC[R0_NW_+D']*],\/^+]&\2Q_\2^Z'G 9:WD^
M61?P[_49%> :]X8U3PW=^1J-N4#?<E7E)/H?Z=:S(9);>9)H9'CE0Y5T;!4^
MH(J(XB<':1O5RVA7CS4M/38^KZ*\K\$_%#SWCTWQ"ZJYPL=YT!]G]/K^?K7J
M@.1D=*[H5(S5T>#7P]2A+EF@HHHJS **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#'\4:['X<\/76I. SHNV)#_&YX4?U^@-?-Z+>Z_K
M:J6::]O9@-S?Q,QKT?XT:J6O-/TE&^5$-Q(/4D[5_(!OSK"^$]BMWXWBE=<B
MVA>4?7A1_P"A5P5GSU5#H?08&"P^%E6>[U_R/:_#^AVOAW1H-.M%&V,?.^.9
M'[L?K6G117<DDK(\&4G)N3W84444R2IJ6F6>KV,EE?0+-!(.5;M[CT/O7@WB
MWP5=^&]4$4227%I,28)0N2?]DX[C]:]IU7Q=H>C%ENK^,RC_ )91?._Y#I^.
M*XZ_^+<:DKI^EL_H\\FW_P =&?YURU_92^)ZGKY<L7!WIP;B^^B/,8O#>M3\
MQ:1?./46[_X5ZI\/-3\06031]:TR_6WQBWN)(6Q'_L,<=/0]NGTYNX^*7B*4
MGRULX1VVQ$_S)JDWQ)\59R+^,?2W3_"N>$Z=-W39Z6(H8G$0Y)PBOF]/P/=Z
M*\.M_BKXD@8&4VEP.X>''_H)%='IOQCM)"$U3398?62!MX_(X/\ .NN.)IOJ
M>/4RO$PUM?T/3J*R](\1Z1KL>[3;Z*<@9* X=?JIY%:E;)IZHX)1E%VDK,**
M**9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\?$ZX-QX_U $\1"
M.,?]\*?YDUL?!ME7Q5=J>K6;8_[[6L'XA*1X_P!7S_ST4_\ CBU:^&MZ+'QO
M9;CA)]T!_P"!#C]0*\Q.U:[[GU,H<V!LOY?T/H.BD9E1&=V"JHR23@ 5Y=XL
M^([RM)8:"Y5!\KW8ZM_N>@]_R]:[ZE2--79\_AL+4Q,^6FO^ =CXA\9:7X>4
MQRR>?=XXMXCEO^!'^'_/%>6ZWXXUK7"T?G&UM3_RQ@)&1[MU/\O:N> :1R[L
M69CDDG))J98Z\VKB9STV1]7@\JHT-6N:7=_H5Q%1Y57 @I\5M)<2K%#$\DC=
M%1<D_@*P/4Y4E=F<8ZB:.N[L/AWK=Z TJ1VB'_GLW/Y#/ZXK1?P!H.G#_B;>
M(51NZ*50_J2?TK94*C5[6//J8_#1?*I7?EK^1Y:R5"ZUZA)8?#>VX>]NIS_L
MES_)0*OV'@+PGXDTXWFF37T4>\IG>."/4$&J5"3T37WG/4Q]."YIQDEW:/'8
MY);>9989'CE0Y5T8@@^Q%>B>%OBS=V3):Z^&NK?H+E1^\3ZC^(?K]:?K'PAU
M*W5I-,O(KM1SY<@\M_PZ@_F*\[U'3;S2[IK:^MI;>9>J2+@_4>H]Z:]I1=]B
M)/#8R-KI_F?45E>VVHVD=W9SI/!(,I(AR#4]?.7@SQG=^%-1'+2Z?*W[^#/_
M (\OHP_7^7T-9WEO?V<-W:RK+!,H='7H0:[J555%YGSV,P<L-+NGLR>BB@D
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MA7<VH74EQ(ER55G.2!M4X_6O(/$/_(RZI_U]R_\ H9KU+X0?\BY>_P#7V?\
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M]0^D?_HM:][KP3XD_P#(]ZA](_\ T6M '0?!W_C_ -5_ZY1_S->MUY)\'?\
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MV^N.#3-/\&:997R7TTEU?W:?<FO9C*4^@Z"NAHH **** "BBB@#'\4Z*NO\
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M'KYM3\.Z?>R',DT",Y_VL<_KFD!X5XXS_P )KJV?^>_]!78_!O'F:QZXB_\
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MI@<_17T7_P (;X;_ .@+9_\ ?NC_ (0WPW_T!;/_ +]T ?.E%?1?_"&^&_\
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MG\/::]W>)C4+H#<O_/-.R_7N?P]*8':5X)\2?^1[U#Z1_P#HM:][KP3XD_\
M(]ZA](__ $6M(#H/@[_Q_P"J_P#7*/\ F:];KR3X._\ '_JO_7*/^9KUN@#Y
MJ\0_\C+JG_7W+_Z&:]2^$'_(N7O_ %]G_P! 6O.?&EF]CXQU2)E(W3M*ON&^
M8?SK>\ >-K+PS:W5G?Q3&.602(\0#8.,$$$CT%,#VNBN'_X6MX<]+S_OR/\
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M_P"_(_QH_P"%K>&_2\_[\C_&@#N**X?_ (6MX<]+S_OR/\:[9'$D:NO1@"*
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M <W,_P S_AV7\*Z2BMX4(0U2.*OCJU96D[+L@HHHK4XPHHHH **** "BBB@
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MUTK7YKB[<I&4=<A2>21Z?2D!ZG17/_\ ":Z'_P _3_\ ?IO\*WU(90PZ$9%
M'G'C/_D;(?\ <C_F:](KS;QJP3Q3$S=%C0G\S73/XXT5%)665SZ+$>?SI@8G
MQ!LXHKBTNT4++*&5R.^,8/ZUV.CSO=:-93R'+O"I8^IQUK@;R>]\:ZQ$EM T
M=M%\H)Y" ]68^OM7HUO EK;16\8PD2!%^@&* .1^(?\ QXV7_75OY5O>&O\
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M3DF6[F<@GN!U/XDG\J]5TG_D#6/_ %[Q_P#H(KDO'L$=MIVF01+MCC+*H]
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'VBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img173561143_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173561143_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (  @ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLOR?_P"*H_X6KJW_ #XV7Y/_ /%5P=%/ZCA_Y!>WJ=SO/^%JZM_SXV7Y/_\
M%4?\+5U;_GQLOR?_ .*K@Z*/J.'_ ) ]O4[G>?\ "U=6_P"?&R_)_P#XJC_A
M:NK?\^-E^3__ !5<'11]1P_\@>WJ=SOE^*VJ C?869'MN']:['PMXTM/$C-
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MBBOC#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA/\ Y&S2O^OE/YUCUL>$_P#D;-*_Z^4_G6=;^'+T9</B1[]1117QA[(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YS\5M2*6]CIB'
M[[&:0>PX7^;?E7E]=1\0;TWGC"Z&<I %A7\!D_J37+U]9@:?L\/%?/[SR:\N
M:HV%%%%=9B%%%% !1110 4444 %%%% !1110 4444 %%%% !6QX3_P"1LTK_
M *^4_G6/72^ ]/EOO%MFR*3';DS2-V4 <?K@5CB&HTI-]F735YI'N-%%%?''
MLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*](^$W^NU7_=B_FU>;UZ1\)O]?JO^[%_-JXLQ_W:7R_-&^'_ (J/3J***^5/
M5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \!\5_P#(V:K_ -?+_P ZQZV/%?\
MR-FJ_P#7R_\ .L>OLZ/\./HCQI_$PHHHK0@**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KTCX3?Z_5?]V+^;5YO7I'PF_U^
MJ_[L7\VKBS'_ ':7R_-&^'_BH].HHHKY4]4**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#P'Q7_R-FJ_]?+_ ,ZQZV/%?_(V:K_U\O\ SK'K[.C_  X^B/&G\3"B
MBBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "O2/A-_KM5_W8OYM7F]>D?"7_ %VK?[L7\VKBS'_=I?+\T;X?^*CTZBBB
MOE3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** / ?%?_(V:K_U\O_.L>MCQ7_R-
MFJ_]?+_SK'K[.C_#CZ(\:?Q,****T("BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *](^$O^NU;_ '8O_9J\WKTCX2_Z[5O]
MV+_V:N+,?]VE\OS1OA_XJ/3J***^5/5"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \.\>6$MCXMO&=2([@B:-NS CG]<BN:KZ)U+2;#5X!#?VL<Z#D;AROT(Y'X
M5S[?#?PXQR+>9?83-_6O=P^:TXTU&HG='!4PLG)N)XM17M'_  K;P[_SRN/^
M_P :/^%;>'?^>5Q_W^-;_P!K4/,CZI4/%Z*]H_X5MX=_YY7'_?XT?\*V\._\
M\KC_ +_&C^UJ'F'U2H>+T5[1_P *V\._\\KC_O\ &J6K_#_0;/1;^ZABG$L-
MO)(A,I(R%)'\J<<UH-I*XGA9I7/)****](Y@HHHH **** "BBB@ HHHH **Z
M'P9I%IK?B%+.]5FA,;-A6P<BO1_^%;>'?^>5Q_W^-<>(QU*A/DG>YO3H2J*Z
M/%Z*]H_X5MX=_P">5Q_W^-'_  K;P[_SRN/^_P :P_M:AYE_5*AXO17M'_"M
MO#O_ #RN/^_QH_X5MX=_YY7'_?XT?VM0\P^J5#Q>BO:/^%;>'?\ GE<?]_C1
M_P *V\._\\KC_O\ &C^UJ'F'U2H>+UZK\*K"6'3KZ^=2$N'5$)[A<Y(_%L?A
M6S;_  ]\-P.'-DTI'022L1^6>:Z6**.")(H8UCC085%& !Z 5QXW,85J?LX)
MZFU##.$N:0^BBBO'.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K-\0_\ (LZK_P!><W_H!K2K-\0_\BSJO_7G-_Z :NE\:]29?"SY[HHH
MK[0\4**** "BBB@ HHHH **** .O^&O_ "-\?_7%_P"5>SUXQ\-?^1OC_P"N
M+_RKV>OF\V_C_(]/"?PPHHHKS#I"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ#_P BSJO_ %YS?^@&M*LW
MQ#_R+.J_]><W_H!JZ7QKU)E\+/GNBBBOM#Q0HHHH **** "BBB@ HHHH Z_X
M:_\ (WQ_]<7_ )5[/7C'PU_Y&^/_ *XO_*O9Z^;S;^/\CT\)_#"BBBO,.D**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *S?$/_ "+.J_\ 7G-_Z :TJS?$/_(LZK_UYS?^@&KI?&O4F7PL^>Z*
M**^T/%"BBB@ HHHH **** "BBB@#K_AK_P C?'_UQ?\ E7L]>,?#7_D;X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img173561143_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173561143_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (  @ # 2(  A$! Q$!_\0
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M#=6[E)X9%DC<=58'(/YBONK0=5CUSP_IVJQ8"7EM'. .VY0<?AG% &A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'PSXMOSJGC'6KXG/GWTSCZ%S@?EBL:G2,7E=F^\Q)--H **** "BBB@ HH
MHH **** "BBB@ HHHH *^NO@=?F^^%6FHQRUM)+ 3]')'Z,*^1:^H_V=&+?#
MFZ!Z+J<H'_?N,_UH ]<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#X,U>U-CK5_:,,&"XDB(]-K$?TJG7<?%_2
M&T?XH:S'MQ'<RB[0^HD&XG_OHL/PKAZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "OJW]G^U-O\ #".4C N;R:4>^,)_[)7RE7VU\/=(.A?#[0].==LD=JKR
M+Z._SL/S8T =+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,1?^ </_ ,31_P +S^('_08B_P# .'_XF@#ZZHKY%_X7G\0/^@Q%_P" </\
M\31_PO/X@?\ 08B_\ X?_B: /KJBOD7_ (7G\0/^@Q%_X!P__$T?\+S^('_0
M8B_\ X?_ (F@#ZZHKY%_X7G\0/\ H,1?^ </_P 31_PO/X@?]!B+_P  X?\
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M-1_^ </_ ,11_P +Q^(/_0:C_P# .'_XB@#Z[HKY$_X7C\0?^@U'_P" </\
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M1_M%_P#).K3_ +"<?_HN6OEROJ/]HO\ Y)U:?]A./_T7+7RY0 4444 %%%%
M!1110 4444 %%%% !7U%^SG_ ,DZO/\ L*2?^BXJ^7:^HOV<_P#DG5Y_V%)/
M_1<5 'KM%%'2@ K@O'OQ7T+P/&]LS"^U;'RV4+?=]#(W\(_7V[UPOQ1^. M'
MFT/PE.K3#*7&HKR$/=8_4_[73T]1\]2RR3S/--(TDKL6=W.2Q/4DGJ: .F\7
M_$+Q%XVN"VJWA%L#F.SARL*?\![GW.37+444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $MM<W%G<QW-K/)!/&=R21.593Z@CD5[?X"^/\ <VIBT[Q>
MK7$'"KJ$:_O$'^VH^\/<<^QKPNB@#[WL;^TU.RBO;&YBN;:9=T<L3!E8>Q%6
M*^,O /Q'U?P%J.ZV8W&G2-FXLG;Y7]U_NM[_ )YKZT\,>*-+\7:)%JNDSB2%
M^&0\/$W=6'8C_P"N.* -FBBB@ HHHH *^#M:_P"0]J/_ %]2?^A&OO&O@[6O
M^0]J/_7U)_Z$: *-%%% !1110 4444 %%%% !1110 4444 ?5G[/W_),5_Z_
M9O\ V6O4Z\L_9^_Y)BO_ %^S?^RUZG0 4444 %%%% !1110!Y'^T7_R3JT_[
M"<?_ *+EKY<KZC_:+_Y)U:?]A./_ -%RU\N4 %%%% !1110 4444 %%%% !1
M110 5]1?LY_\DZO/^PI)_P"BXJ^7:^HOV<_^2=7G_84D_P#1<5 'KM?.WQD^
M+K7;W'A?PY<8MES'>WD;?ZT]XT/]WL3WZ=.O1?'#XEG0[-O#&CSE=2N4S=3(
M>8(C_"#V9A^0^H-?,] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5U/@3QSJ/@37DO[-C);.0MU:EL+,G]&'8]OH2#RU% 'W;H.
MNV'B71+;5M,F\VUN%W*>ZGNI'8@\$5I5\F?!SXB/X.\0#3[^8C1;]PLNX\02
M=!)[#L?;GL*^LP00"#D'O0 4444 %?!VM?\ (>U'_KZD_P#0C7WC7P=K7_(>
MU'_KZD_]"- %&BBB@ HHHH **** "BBB@ HHHH **** /JS]G[_DF*_]?LW_
M ++7J=>6?L_?\DQ7_K]F_P#9:]3H **** "BBB@ HHHH \C_ &B_^2=6G_83
MC_\ 1<M?+E?4?[1?_).K3_L)Q_\ HN6OER@ HHHH **** "BBB@ HHHH ***
M* "OH#X6>*[?P9\#M8UB?:TB:E(EO$3_ *V4Q1[5_J?8&OG^I3=7!M!:&>4V
MP<R"'>=@<C!;;TS@ 9H EU'4+K5M2N=0OIFFNKF0R2R-U9B<FJM%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?4_P "
MO'!\1^&#HM[+NU'2U"*6/,D'13]5^Z?^ ^M?+%=+X"\4R^#O&5AJZ%O)1_+N
M4'\<+<,/RY'N!0!]M44R*6.>))8G5XW4,K*<A@>013Z "O@[6O\ D/:C_P!?
M4G_H1K[QKX.UK_D/:C_U]2?^A&@"C1110 4444 %%%% !1110 4444 %%%%
M'U9^S]_R3%?^OV;_ -EKU.O+/V?O^28K_P!?LW_LM>IT %%%% !1110 4444
M >1_M%_\DZM/^PG'_P"BY:^7*^H_VB_^2=6G_83C_P#1<M?+E !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!]9_ SQ,=>^'T-I-)NNM+?[*^3R8^
ML9^F/E_X#7IE?*_[/^O_ -E^/FTR1\0:I 8\=O,3YE/Y!Q_P*OJB@ KX.UK_
M )#VH_\ 7U)_Z$:^\:^#M:_Y#VH_]?4G_H1H HT444 %%%% !1110 4444 %
M%%% !1110!]6?L_?\DQ7_K]F_P#9:]3KRS]G[_DF*_\ 7[-_[+7J= !1110
M4444 %%%% 'D?[1?_).K3_L)Q_\ HN6OEROJ/]HO_DG5I_V$X_\ T7+7RY0
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MHH **** "BBB@ HHHH **** "BBB@ K=\,^#]=\7WIMM%T^2X*G]Y+]V./\
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M%%% !1110 4444 ?5G[/W_),5_Z_9O\ V6O4Z\L_9^_Y)BO_ %^S?^RUZG0
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M0]J/_7U)_P"A&@"C1110 4444 %%%% !1110 4444 %%%% 'U9^S]_R3%?\
MK]F_]EKU.O+/V?O^28K_ -?LW_LM>IT %%%% !1110 4444 >1_M%_\ ).K3
M_L)Q_P#HN6OEROJ/]HO_ ))U:?\ 83C_ /1<M?+E !1110 4444 %%%% !11
M10 4444 %3V,'VJ_MK?_ )ZRJGYD"H*U?#$?F^+-&C_OWT"_G(M 'W5THHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \Q^/D>_X6W+8_U=S"W_ (]C^M?)
MU?7/QS&?A-JA])(#_P"15KY&H **** "BBB@ HHHH **** "BBB@ I0<$'TI
M** /O^O@[6O^0]J/_7U)_P"A&OO&O@[6O^0]J/\ U]2?^A&@"C1110 4444
M%%%% !1110 4444 %%%% 'U9^S]_R3%?^OV;_P!EKU.O+/V?O^28K_U^S?\
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M1110 4444 %%%% 'U9^S]_R3%?\ K]F_]EKU.O+/V?O^28K_ -?LW_LM>IT
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MG7EG[/W_ "3%?^OV;_V6O4Z "BBB@ HHHH **** /(_VB_\ DG5I_P!A./\
M]%RU\N5]1_M%_P#).K3_ +"<?_HN6OER@ HHHH **** "BBB@ HHHH ****
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M44 ??]?!VM?\A[4?^OJ3_P!"-?>-?!VM?\A[4?\ KZD_]"- %&BBB@ HHHH
M**** "BBB@ HHHH **** /JS]G[_ ))BO_7[-_[+7J=>6?L_?\DQ7_K]F_\
M9:]3H **** "BBB@ HHHH \C_:+_ .2=6G_83C_]%RU\N5]1_M%_\DZM/^PG
M'_Z+EKY<H **** "BBB@ HHHH **** "BBB@ K<\%_\ (]>'O^PG;?\ HU:P
MZW/!?_(]>'O^PG;?^C5H ^XZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M//OC?_R2+6_K;_\ H^.OD&OK[XW_ /)(M;^MO_Z/CKY!H **** "BBB@ HHH
MH **** "BBB@ HHHH ^_Z^#M:_Y#VH_]?4G_ *$:^\:^#M:_Y#VH_P#7U)_Z
M$: *-%%% !1110 4444 %%%% !1110 4444 ?5G[/W_),5_Z_9O_ &6O4Z\L
M_9^_Y)BO_7[-_P"RUZG0 4444 %%%% !1110!Y'^T7_R3JT_["<?_HN6OERO
MJ/\ :+_Y)U:?]A./_P!%RU\N4 %%%% !1110 4444 %%%% !1110 5N>"_\
MD>O#W_83MO\ T:M8=;G@O_D>O#W_ &$[;_T:M 'W'1110 4444 %%%% !111
M0 4444 %%%% !1110!Y]\;_^21:W];?_ -'QU\@U]??&_P#Y)%K?UM__ $?'
M7R#0 4444 %%%% !1110 4444 %%%% !1110!]_U\':U_P A[4?^OJ3_ -"-
M?>-?!VM?\A[4?^OJ3_T(T 4:*** "BBB@ HHHH **** "BBB@ HHHH ^K/V?
MO^28K_U^S?\ LM>IUY9^S]_R3%?^OV;_ -EKU.@ HHHH **** "BBB@#R/\
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; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img173561143_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173561143_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (  @ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\
M[51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M
M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C
M_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_
M )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\
M--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!17S__ ,--?]2C_P"5+_[51_PT
MU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\ [51_PTU_U*/_ )4O_M5 'T!1
M7S__ ,--?]2C_P"5+_[51_PTU_U*/_E2_P#M5 'T!17S_P#\--?]2C_Y4O\
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MRD7\;?CG:/J?2OE&O1/C;KW]N?$R^C1]T&GJMG']5Y?_ ,?+#\*\[H ****
M"BBB@ HKK/ 5[X2@UH6_C#21=Z?.0OVA9I4:W/\ >PC#<OKW[CT/TA!\&?AO
M<P1SP:&DL,BATD2^G*LIY!!$G(H ^0Z*^O\ _A27P\_Z%[_R=N/_ (Y1_P *
M2^'G_0O?^3MQ_P#'* /D"BOK_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3M
MQ_\ '* /D"BOK_\ X4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QR@#Y
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M *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<H ^0**^O_\ A27P\_Z%[_R=N/\
MXY1_PI+X>?\ 0O?^3MQ_\<H ^0**^O\ _A27P\_Z%[_R=N/_ (Y1_P *2^'G
M_0O?^3MQ_P#'* /D"BOK_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\
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M /D"BOK_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\ QR@#Y HKZ_\
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M SP!DG\J &T444 %>L?"7XM2^$IX]&UJ1Y=#D;".<EK1CW'JGJ.W4=P?)Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK*>XH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\=Q:SH'CEC.58'O0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M" P((!!X(-+10!\W_%_X/G2C/XD\-VY-@<O=V<8_U'JZ#^YZC^'Z=/$*^_B
M001D'J#7SC\8/@^=,,_B3PU;YL3E[NSC'^H]70?W/4?P_3H >'T444 %>C_"
MWXI7?@:^%E>F2XT*=\RQ#EH2?XT_J._UKSBB@#[WL+^TU2P@OK&XCN+6= \<
ML9R&!JQ7R-\+OBE=^!;\6=X9+C0YWS+".3"3_&G]1W^M?6&GZA::K807UC<1
MW%K.@>.6,Y# T 6:*** "BBB@ HHHH **** "BBB@ HHHH *KW]_::783WU]
M<1V]K A>260X"@4FH:A::583WU]<1V]K A>260X"@5\G_%'XI7?CJ_-G9F2W
MT.!\Q0G@S$?QO_0=OK0 OQ2^*5WXYOC961DM]"@?,41X:8C^-_Z#M]:\XHHH
M **** "O;_A!\'SJI@\2>)+<BP&'M+.0?Z_T=Q_<]!_%].J_!_X/G4S!XD\2
MV^+$8>TLY!_K_1W']ST'\7TZ_1P    P!T H   H    X %+110 4444 %%%
M% !1110 4444 %%%% !1110!\@?&W_DKVN_]N_\ Z3QUY_7H'QM_Y*]KO_;O
M_P"D\=>?T %%%% !1110 5Z!\$O^2O:%_P!O'_I/)7G]>@?!+_DKVA?]O'_I
M/)0!]?T444 %%%% !1110 4444 %%%% !1110 444$X&30 =*^=OC!\8?MGG
M^&O#-Q_HW,=Y>QG_ %OJB'^[ZGOT''5OQ@^,/V[S_#7AFX_T7E+R]C/^M]40
M_P!WU/?H..OA= !1110 4444 %>B_"[XHW?@6_%I=F2XT.=\S0CDPD_QI[^H
M[_6O.J* /O;3]0M-5T^"_L+B.XM9T#QRQG(859KY$^%_Q1O/ FH"UNC)<:'.
M^9H <F(_WT]_4=_KS7UEIVHV>K:?!?V%Q'<6LZ!XY8SD,/\ /:@"S1110 44
M44 %%%% !1110 56U#4+32M/GO[^XCM[6!"\DLAP%%&HZC9Z3I\]_?W$=O:P
M(7DED. H_P ]J^3?BA\4;SQWJ!M;4R6^AP/F& G!E/\ ??W]!V^O- "_%'XH
MW?CJ_-I:&2WT.!\PPG@S$?QO[^@[?6O.J** "BBB@ HHHH ]V^#_ ,8?L?D>
M&O$UQ_HW$=G>R'_5>B.?[OH>W0\=/HGK7P!7NGP?^,/V'R/#7B:X_P!%X2SO
M9#_JO1'/]WT/;H>.@!]%T4 Y&110 4444 %%%% !1110 4444 %%%% !1110
M!\@?&W_DKVN_]N__ *3QUY_7H'QM_P"2O:[_ -N__I/'7G] !1110 4444 %
M>@?!+_DKVA?]O'_I/)7G]>@?!+_DKVA?]O'_ *3R4 ?7]%%% !1110 4444
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MHH **** "O0/@E_R5[0O^WC_ -)Y*\_KT#X)?\E>T+_MX_\ 2>2@#Z_HHHH
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M-:^$_C;0F<SZ%<7$2_\ +6S'GJ1ZX7) ^H% '%T4^6&6WD,<T;QR+U5U((_
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ML*0P1*$CCC7"JHX  ["I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I/'7G]>@?&W_DKVN_\ ;O\ ^D\=>?T %%%% !1110 5Z!\$O^2O:%_V\?\
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MU'TC!\9OAM;01P0:XD4,:A$C2QG"JHX  $? KY#HH ^O_P#A=OP\_P"AA_\
M)*X_^-T?\+M^'G_0P_\ DE<?_&Z^0** /K__ (7;\//^AA_\DKC_ .-T?\+M
M^'G_ $,/_DE<?_&Z^0** /K_ /X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE
M<?\ QNOD"B@#Z_\ ^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'_P ;KY H
MH ^O_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z^0** /K__ (7;
M\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&Z^0** /K_ /X7;\//^AA_\DKC
M_P"-T?\ "[?AY_T,/_DE<?\ QNOD"B@#Z_\ ^%V_#S_H8?\ R2N/_C='_"[?
MAY_T,/\ Y)7'_P ;KY HH ^O_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\
MDE<?_&Z^0** /K__ (7;\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&Z^0**
M /K_ /X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE<?\ QNOD"B@#Z_\ ^%V_
M#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'_P ;KY HH ^O_P#A=OP\_P"AA_\
M)*X_^-T?\+M^'G_0P_\ DE<?_&Z^0** /K__ (7;\//^AA_\DKC_ .-T?\+M
M^'G_ $,/_DE<?_&Z^0** /K_ /X7;\//^AA_\DKC_P"-T?\ "[?AY_T,/_DE
M<?\ QNOD"B@#Z_\ ^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\ Y)7'_P ;KY H
MH ^O_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\ DE<?_&Z^0** /K__ (7;
M\//^AA_\DKC_ .-T?\+M^'G_ $,/_DE<?_&Z^0** /K_ /X7;\//^AA_\DKC
M_P"-T?\ "[?AY_T,/_DE<?\ QNOD"B@#Z_\ ^%V_#S_H8?\ R2N/_C='_"[?
MAY_T,/\ Y)7'_P ;KY HH ^O_P#A=OP\_P"AA_\ )*X_^-T?\+M^'G_0P_\
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MT?\ #,O_ %-W_E-_^VU] 44 ?/\ _P ,R_\ 4W?^4W_[;1_PS+_U-W_E-_\
MMM?0%% 'S_\ \,R_]3=_Y3?_ +;1_P ,R_\ 4W?^4W_[;7T!10!\_P#_  S+
M_P!3=_Y3?_MM'_#,O_4W?^4W_P"VU] 44 ?/_P#PS+_U-W_E-_\ MM'_  S+
M_P!3=_Y3?_MM?0%% 'S_ /\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;7T!10
M!\__ /#,O_4W?^4W_P"VT?\ #,O_ %-W_E-_^VU] 44 ?/\ _P ,R_\ 4W?^
M4W_[;1_PS+_U-W_E-_\ MM?0%% 'S_\ \,R_]3=_Y3?_ +;1_P ,R_\ 4W?^
M4W_[;7T!10!\_P#_  S+_P!3=_Y3?_MM'_#,O_4W?^4W_P"VU] 44 ?/_P#P
MS+_U-W_E-_\ MM'_  S+_P!3=_Y3?_MM?0%% 'S_ /\ #,O_ %-W_E-_^VT?
M\,R_]3=_Y3?_ +;7T!10!\__ /#,O_4W?^4W_P"VT?\ #,O_ %-W_E-_^VU]
M 44 ?/\ _P ,R_\ 4W?^4W_[;1_PS+_U-W_E-_\ MM?0%% 'S_\ \,R_]3=_
MY3?_ +;1_P ,R_\ 4W?^4W_[;7T!10!\_P#_  S+_P!3=_Y3?_MM'_#,O_4W
M?^4W_P"VU] 44 ?/_P#PS+_U-W_E-_\ MM'_  S+_P!3=_Y3?_MM?0%% 'S_
M /\ #,O_ %-W_E-_^VT?\,R_]3=_Y3?_ +;7T!10!\__ /#,O_4W?^4W_P"V
MT?\ #,O_ %-W_E-_^VU] 44 ?/\ _P ,R_\ 4W?^4W_[;1_PS+_U-W_E-_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
